NEW YORK, March 03, 2020 -- Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a medical technology company focused on Women’s Health, initially in the breast.
Last week, you might have seen that Establishment Labs Holdings Inc. (NASDAQ:ESTA) released its yearly result to the...
Ladies and gentlemen, thank you for standing by, and welcome to Establishment Labs' First Quarter 2020 Earnings Conference Call. Before we begin, I would like to introduce David Erickson, was recently joined Establishment Labs as Vice President of Investor Relations.
As of late, it has definitely been a great time to be an investor Establishment Labs
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Establishment Labs Holdings Inc. (NASDAQ:ESTA). Establishment Labs Holdings Inc. (NASDAQ:ESTA) […]
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
NEW YORK, May 26, 2020 -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and.
Establishment Labs Holdings Inc. (ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the fourth quarter and full year ended December 31, 2019.
BTIG analyst Marie Thibault reiterated a Buy rating on Establishment Labs Holdings (NASDAQ:ESTA) Inc on Thursday, setting a price target of $35, which is approximately 95.20% above the present share price of $17.93.
Establishment Labs Holdings Inc. (ESTA), a medical technology company focused on Women’s Health – initially in the breast aesthetics and reconstruction market – announced its one millionth Motiva® implant in market. Most importantly, we achieved this milestone while maintaining less than a 1% complication rate for events related to Motiva Implants®.
Establishment Labs Holdings Inc. (ESTA) (the “Company”), a medical technology company focused on Women’s Health – initially in the breast aesthetics and reconstruction market – today announced the closing of its previously announced public offering of 2,628,571 common shares at $26.25 per share. This includes the exercise in full by the underwriters of their option to purchase up to 342,857 additional common shares. The gross proceeds to Establishment Labs were approximately $69.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Establishment Labs.
Establishment Labs Holdings Inc. (ESTA) (the “Company”), a medical technology company focused on Women’s Health – initially in the breast aesthetics and reconstruction market – today announced the pricing of its public offering of 2,285,714 common shares at $26.25 per share. The gross proceeds to Establishment Labs, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $60.0 million. The offering is scheduled to close on February 3, 2020, subject to the satisfaction of customary closing conditions.
NEW YORK, May 07, 2020 -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and.
NEW YORK, April 23, 2020 -- Establishment Labs Holdings Inc. (Nasdaq: ESTA), a medical technology company focused on Women’s Health, initially in the breast aesthetics and.
Establishment Labs Holdings Inc. (ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that the U.S. Patent & Trademark Office has issued a patent protecting its proprietary implant surface technology. The ‘979 patent epitomizes the Company’s dedication to improving patient safety and post-operative outcomes by advancing technology. “This patent protects the fundamental characteristics of the unique surface technology found in our popular Motiva Implants, currently available to patients in over 80 countries and now being studied in our U.S. clinical trial,” said Juan José Chacón-Quirós, Chief Executive Officer.
NEW YORK, Feb. 25, 2020 -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on Women’s Health – initially in the breast aesthetics and.
NEW YORK, May 11, 2020 -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and.
Establishment Labs Holdings Inc. (ESTA) (the “Company”), a medical technology company focused on Women’s Health – initially in the breast aesthetics and reconstruction market – today announced that it has commenced a public offering of approximately $55,000,000 of its common shares, to be sold by the Company in a registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to $8,250,000 of additional common shares.
Establishment Labs Holdings Inc. (ESTA), a medical technology company focused on Women’s Health – initially in the breast aesthetics and reconstruction market – today announced preliminary financial results for the fourth quarter and full year 2019, with total revenue growth for the quarter of 43% to 49%. “2019 was another extraordinary year for Establishment Labs, and we ended the year on a strong note with our sixth consecutive quarter of record revenue performance,” said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. Preliminary and unaudited revenue for the fourth quarter of 2019 is expected to be in the range of $23.5 million and $24.5 million, representing growth of approximately 43% to 49% over the fourth quarter of 2018.
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of -19.23% and 14.27%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?